Pharming (PHAR) Total Non-Current Liabilities (2019 - 2025)
Historic Total Non-Current Liabilities for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $121.2 million.
- Pharming's Total Non-Current Liabilities rose 112.11% to $121.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.2 million, marking a year-over-year increase of 112.11%. This contributed to the annual value of $105.1 million for FY2024, which is 3671.35% down from last year.
- Pharming's Total Non-Current Liabilities amounted to $121.2 million in Q3 2025, which was up 112.11% from $118.8 million recorded in Q2 2025.
- In the past 5 years, Pharming's Total Non-Current Liabilities ranged from a high of $166.1 million in Q4 2023 and a low of $135375.0 during Q3 2022
- Over the past 5 years, Pharming's median Total Non-Current Liabilities value was $121.2 million (recorded in 2025), while the average stood at $113.7 million.
- In the last 5 years, Pharming's Total Non-Current Liabilities plummeted by 9991.57% in 2022 and then soared by 11695780.24% in 2023.
- Quarter analysis of 5 years shows Pharming's Total Non-Current Liabilities stood at $159098.9 in 2021, then skyrocketed by 101384.66% to $161.5 million in 2022, then grew by 2.88% to $166.1 million in 2023, then crashed by 36.71% to $105.1 million in 2024, then rose by 15.32% to $121.2 million in 2025.
- Its last three reported values are $121.2 million in Q3 2025, $118.8 million for Q2 2025, and $110.4 million during Q1 2025.